Escolar Documentos
Profissional Documentos
Cultura Documentos
1. INTRODUÇÃO - REMDESIVIR
4http://www.inpi.gov.br/menu-
servicos/patente/arquivos/CovidPortaria149de03.04.20RPI2570de07.04.20.
pdf
8. REFERÊNCIAS BIBLIOGRÁFICAS press). Disponível online em 03 de abril de 2020.
https://doi.org/10.1016/j.antiviral.2020.104786
(1) PubChem
https://pubchem.ncbi.nlm.nih.gov/compound/121304016 (12) C. J. Gordon, E. P. Tchesnokov, et al. The antiviral
acesso em: 17/04/2020 compound Remdesivir potently inhibits RNA-dependent RNA
polymerase from Middle East respiratory syndrome
(2) J. M. Sanders; M. L. Monogue, et al. Pharmacologic coronavirus.
Treatments for Coronavirus Disease 2019 (COVID-19). A
Review. JAMA, 2020. Disponível online em 13 de abril de (13) R. N. Kirchdoerfer. Halting coronavirus polymerase.
2020. https://doi.org/10.1001/jama.2020.6019 Journal of Biological Chemistry (JBC), vol. 295, n. 15, p.
4780–4781, 2020. https://doi.org/10.1074/jbc.H120.013397
(3) E. Susan Amirian, Julie K. Levy. Current knowledge about
the antivirals Remdesivir (GS-5734) and GS-441524 as (14) T. P. Sheahan, A. C. Sims, et al. Comparative
therapeutic options for coronaviruses. One Health, vol. 9, therapeutic efficacy of Remdesivir and combination lopinavir,
junho, 2020 (In press). Disponível online em 27 de março de ritonavir, and interferon beta against MERS-CoV. Nature
2020. https://doi.org/10.1016/j.onehlt.2020.100128 Communication vol. 11, n. 222, 2020.
https://doi.org/10.1038/s41467-019-13940-6
(4) Wen-Chien K., J. Rolain, et al. Arguments in favour of
Remdesivir for treating SARS-CoV-2 infections. International (15) W.-C. Ko, J.-M. Rolain, et al., Arguments in favour of
Journal of Antimicrobial Agents, 2020 (In press). Disponível Remdesivir for treating SARS-CoV-2 infections. International
online em 06 de março de 2020. Journal of Antimicrobial Agents, 2020 (In press). Disponível
https://doi.org/10.1016/j.ijantimicag.2020.105933 online em 06 de março de 2020.
https://doi.org/10.1016/j.ijantimicag.2020.105933
(5) A. A. Elfiky. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir,
and Tenofovir against SARS-CoV-2 RNA dependent RNA (16) E. de Wit, F. Feldmann, et al. Prophylactic and
polymerase (RdRp): A molecular docking study. Life therapeutic Remdesivir (GS-5734) treatment in the rhesus
Sciences, 2020 (In Press). Disponível online em 25 de março macaque model of MERS-CoV infection. PNAS, vol. 117, no.
de 2020. https://doi.org/10.1016/j.lfs.2020.117592 12, p. 6771-6776 (2020).
https://doi.org/10.1073/pnas.1922083117
(6) B. R. Beck, B. Shin. Predicting commercially available
antiviral drugs that may act on the novel coronavirus (SARS- (17) A. Le Bras, A. Efficacy of Remdesivir in a rhesus
CoV-2) through a drug-target interaction deep learning macaque model of MERS-CoV infection. Lab Anim (2020).
model. Computational and Structural Biotechnology Journal. https://doi.org/10.1038/s41684-020-0537-x
Vol. 18, p. 784-790, 2020.
https://doi.org/10.1016/j.csbj.2020.03.025 (18) World Health Organization – Landscape Analysis of
Candidate Therapeutics for COVID-19. Disponível em:
(7) D. C. Hall Jr; Hai-Feng Ji. A search for medications to https://app.powerbi.com/view?r=eyJrIjoiNjQxZWZhOTItYzU1
treat COVID-19 via in silico molecular docking models of the ZS00Y2QxLWE1ODAtOTViZjhmNyZjNiIiwidCI6ImY2MTBjM
SARS-CoV-2 spike glycoprotein and 3CL protease. Travel GI3LWJkMjQtNGIzOS04MTBiLTNkYzI4MGFmYjU5MCIsIm
Medicine and Infectious Disease, 2020 (In press). Disponível MiOjh9 Acesso em: 21/04/2020
online em 12 de abril de 2020.
https://doi.org/10.1016/j.tmaid.2020.101646 (19) U.S. National Library of Medicice. Disponível em:
https://clinicaltrials.gov Acesso em: 21/04/2020
(8) A. Shannon, N. Thi-Tuyet Le, et al. Remdesivir and
SARS-CoV-2: Structural requirements at both nsp12 RdRp (20) EU Clinical Trials Register. Disponível em:
and nsp14 Exonuclease active-sites. Antiviral Research, vol. https://www.clinicaltrialsregister.eu/ctr-
178, p. 2020. (In press). Disponível online em 10 de abril de search/search?query=covid-19 Acesso em: 21/04/2020
2020. https://doi.org/10.1016/j.antiviral.2020.104793
(21) Yeming Wang, MD et al. Remdesivir in adults with
(9) M. Wang, R. Cao, et al. Remdesivir and chloroquine severe COVID-19: a randomised, double-blind, placebo-
effectively inhibit the recently emerged novel coronavirus controlled, multicentre trial. The Lancet. Acesso em
(2019-nCoV) in vitro. Cell Research, vol. 30, p. 269–271, 01/05/2020. https://doi.org/10.1016/S0140-6736(20)31022-9.
2020. https://doi.org/10.1038/s41422-020-0282-0
(22) NIH Clinical Trial Shows Remdesivir Accelerates
(10) J. Reina. Remdesivir, the antiviral hope against SARS- Recovery from Advanced COVID-19. (29/04/2020) Acessado
CoV-2. Revista Española de Quimioterapia, 1 abril 2020. em: https://www.niaid.nih.gov/news-events/nih-clinical-trial-
http://www.doi.org/10.37201/req/028.2020 shows-remdesivir-accelerates-recovery-advanced-covid-19
Data
Fármacos N° de estimada
País Código Título STATUS
testados participantes para os
resultados
EUA1 NCT04302766 Intermediate-Size Patient Population Expanded Remdesivir - Acessível -
Access Treatment Protocol for Coronavirus Disease
2019 (COVID-19) Remdesivir (RDV; GS-5734™)
EUA1 NCT04292730 A Phase 3 Randomized Study to Evaluate the Remdesivir 1600 Recrutando Maio 2020
Safety and Antiviral Activity of Remdesivir (GS-
5734™) in Participants With Moderate COVID-19
Compared to Standard of Care Treatment
EUA1 NCT04292899 A Phase 3 Randomized Study to Evaluate the Remdesivir 2400 Recrutando Maio 2020
Safety and Antiviral Activity of Remdesivir (GS-
5734™) in Participants With Severe COVID-19
EUA1 NCT04323761 Expanded Access Treatment Protocol: Remdesivir Remdesivir - Acessível -
(RDV; GS-5734) for the Treatment of SARS-CoV2
(CoV) Infection
EUA1 NCT04280705 A Multicenter, Adaptive, Randomized Blinded Remdesivir 440 Recrutando Abril 202
Controlled Trial of the Safety and Efficacy of
Investigational Therapeutics for the Treatment of
COVID-19 in Hospitalized Adults
EUA1 NCT04321616 The (Norwegian) NOR Solidarity Multicenter Trial on Remdesivir e 700 Ainda não Novembro
the Efficacy of Different Anti-viral Drugs in SARS-
hidroxi- recrutado 2020
CoV-2 Infected Patients
cloroquina
EUA1 NCT04315948 Multi-centre, Adaptive, Randomized Trial of the Remdesivir; 3100 Recrutando Março 2023
Safety and Efficacy of Treatments of COVID-19 in
Lopinavir/rito
Hospitalized Adults
navir;
Interferon
Beta-1A;
Hidroxi-
cloroquina
EUA1 NCT04252664 A Phase 3 Randomized, Double-blind, Placebo- Remdesivir; 308 Suspenso 27 de abril
controlled Multicenter Study to Evaluate the Efficacy
Remdesivir de 2020
and Safety of Remdesivir in Hospitalized Adult
Patients With Mild and Moderate COVID-19. placebo
EUA1 NCT04257656 A Phase 3 Randomized, Double-blind, Placebo- Remdesivir; 237 Finalizado 10 de abril
controlled, Multicenter Study to Evaluate the
Remdesivir de 2020
Efficacy and Safety of Remdesivir in Hospitalized
Adult Patients With Severe COVID-19. placebo
Europa2 2020-001052-18 A Multicenter, Adaptive, Randomised Blinded Remdesivir Não informado Sem Não
Controlled Trial of the Safety and Efficacy of
DK, GB, resultado informado
Investigational Therapeutics for the Treatment of
GR, ES COVID-19 in Hospitalized Adults - Version for disponível
European Union
Europa2 2020-000841-15 A Phase 3 Randomized Study to Evaluate the Remdesivir Não informado Sem Não
Safety and Antiviral Activity of Remdesivir (GS-
DE, ES, resultado informado
5734™) in Participants with Severe COVID-19
FR, IT, disponível
NL, GB,
SE
Europa2 2020-000842-32 A Phase 3 Randomized Study to Evaluate the Remdesivir Não informado Sem Não
Safety and Antiviral Activity of Remdesivir (GS-
DE, ES, resultado informado
5734™) in Participants with Moderate COVID-19
FR, IT, Compared to Standard of Care Treatment disponível
NL, GB,
SE
Europa2 2020-000936-23 Multi-centre, adaptive, randomized trial of the safety Remdesivir Não informado Sem Não
and efficacy of treatments of COVID-19 in
FR resultado informado
hospitalized adults
disponível
Legenda: 1 - https://clinicaltrials.gov/; 2- https://www.clinicaltrialsregister.eu